S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The Day of Financial Reckoning Is Near (Ad)
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
The Day of Financial Reckoning Is Near (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The Day of Financial Reckoning Is Near (Ad)
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The Day of Financial Reckoning Is Near (Ad)
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
The Day of Financial Reckoning Is Near (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The Day of Financial Reckoning Is Near (Ad)
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The Day of Financial Reckoning Is Near (Ad)
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
The Day of Financial Reckoning Is Near (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The Day of Financial Reckoning Is Near (Ad)
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The Day of Financial Reckoning Is Near (Ad)
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
The Day of Financial Reckoning Is Near (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The Day of Financial Reckoning Is Near (Ad)
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
TSE:APS

Aptose Biosciences - APS Stock Forecast, Price & News

C$1.08
-0.01 (-0.92%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
C$1.08
C$1.11
50-Day Range
C$0.93
C$1.17
52-Week Range
C$0.90
C$3.91
Volume
6,055 shs
Average Volume
29,803 shs
Market Capitalization
C$99.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$8.50

Aptose Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
687.0% Upside
C$8.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
C$3,376 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

APS stock logo

About Aptose Biosciences (TSE:APS) Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Aptose Biosciences Price Performance

Shares of APS Stock traded down C$0.02 during trading hours on Friday, reaching C$1.07. The company had a trading volume of 6,055 shares, compared to its average volume of 29,803. Aptose Biosciences has a 12-month low of C$0.90 and a 12-month high of C$3.91. The company has a debt-to-equity ratio of 0.72, a quick ratio of 6.70 and a current ratio of 6.89. The company has a market capitalization of C$98.76 million and a price-to-earnings ratio of -1.26. The stock has a fifty day moving average of C$1.06 and a 200-day moving average of C$1.33.

Analyst Upgrades and Downgrades

Separately, Jonestrading restated a "buy" rating and issued a C$5.00 price objective on shares of Aptose Biosciences in a report on Friday, June 3rd.

Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Stock News Headlines

Aptose Reports Results for the First Quarter 2022
Aptose Reports Results for the Third Quarter 2021
Aptose Reports Results for the Second Quarter 2021
Were Hedge Funds Right About Cutera, Inc. (CUTR)?
See More Headlines
Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Company Calendar

Today
8/20/2022
Next Earnings (Estimated)
11/10/2022

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$8.50
High Stock Price Forecast
C$12.00
Low Stock Price Forecast
C$5.00
Forecasted Upside/Downside
+687.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.70 per share
Book Value
C$0.60 per share

Miscellaneous

Free Float
N/A
Market Cap
C$99.68 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. William G. Rice Ph.D. (Age 59)
    Chairman, Pres & CEO
  • Mr. Gregory K. Chow CPA (Age 45)
    MBA, BA, Sr. VP, CFO & Principal Accounting Officer
  • Mr. Ernest Kitt B.S.
    M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell (Age 73)
    Chief Medical Officer
  • Mr. Peter Murray
    Director of Clinical Devel.













APS Stock - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APS shares.
View APS analyst ratings
or view top-rated stocks.

What is Aptose Biosciences' stock price forecast for 2022?

3 Wall Street research analysts have issued 12 month price objectives for Aptose Biosciences' shares. Their APS share price forecasts range from C$5.00 to C$12.00. On average, they anticipate the company's share price to reach C$8.50 in the next year. This suggests a possible upside of 694.4% from the stock's current price.
View analysts price targets for APS
or view top-rated stocks among Wall Street analysts.

How have APS shares performed in 2022?

Aptose Biosciences' stock was trading at C$1.73 at the beginning of the year. Since then, APS shares have decreased by 38.2% and is now trading at C$1.07.
View the best growth stocks for 2022 here
.

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our APS earnings forecast
.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), AltaGas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD).

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APS."

How do I buy shares of Aptose Biosciences?

Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Aptose Biosciences' stock price today?

One share of APS stock can currently be purchased for approximately C$1.07.

How much money does Aptose Biosciences make?

Aptose Biosciences (TSE:APS) has a market capitalization of C$98.76 million.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The official website for the company is aptose.com. The biotechnology company can be reached via phone at +1-647-4799828.

This page (TSE:APS) was last updated on 8/20/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.